Combining selective serotonin reuptake inhibitors and cognitive behavioral therapy in youth with depression and anxiety

Jeffrey R. Strawn*, Jeffrey A. Mills, Vikram Suresh, Tara S. Peris, John T. Walkup, Paul E. Croarkin

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Treatment studies of children and adolescents with internalizing disorders suggest that the combination of a selective serotonin reuptake inhibitor (SSRI) and cognitive behavioral therapy (CBT) consistently produces greater improvement than either treatment alone. We sought to determine how response to combined treatment varies across disorders (anxiety versus depression), and by specific patient characteristics. Methods: Three large National Institutes of Health-funded trials of children and adolescents with major depression (n = 2) and anxiety disorders (n = 1) were evaluated, each comparing CBT + SSRI to SSRI only, Bayesian Hierarchical Models (BHMs) were used, for endpoint response, time course of response and predictors of response in participants who received SSRI or SSRI+CBT. Results: SSRI+CBT significantly decreased symptoms by week 4 (p<0.001) across disorders. This improvement continued at week 8 and 12 (p<0.001); however, the additive benefit of CBT over SSRI monotherapy was not statistically significant until week 12 (p<0.001). The fastest response to SSRI+CBT was for patients who were younger, with milder baseline anxiety/depression symptoms and depressive disorders. The slowest response for SSRI+CBT was for boys, adolescents, minoritized children, those with severe symptoms and externalizing disorders. Limitations: Limitations included inconsistent moderators, variation in the number of observations over time and a lack of genetic or pharmacokinetic variables related to SSRI exposure across studies. Conclusions: The superiority of SSRI+CBT for youth with depression and anxiety is further supported. For purposes of rapid and greater relief, combination treatment is the superior approach across anxiety and depression and is robust to a range of participant characteristics. However, the added value of CBT (with an SSRI) occurs late in treatment. These findings represent a step towards understanding heterogeneity of treatment response and raise the possibility that interventions could be better tailored or adapted based on patient characteristics.

Original languageEnglish (US)
Pages (from-to)292-300
Number of pages9
JournalJournal of Affective Disorders
Volume298
DOIs
StatePublished - Feb 1 2022

Keywords

  • Anxiety
  • Clinical trial
  • Depression
  • Fluoxetine
  • Major depressive disorder
  • Paroxetine
  • SSRI
  • Sertraline

ASJC Scopus subject areas

  • Clinical Psychology
  • Psychiatry and Mental health

Fingerprint

Dive into the research topics of 'Combining selective serotonin reuptake inhibitors and cognitive behavioral therapy in youth with depression and anxiety'. Together they form a unique fingerprint.

Cite this